Open AccessKSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future
Author(s) -
Byung Hyun Byun,
Myoung Hyoun Kim,
Young Jin Han,
Hwan-Jeong Jeong
Publication year - 2021
Publication title -
nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.534
H-Index - 23
eISSN - 1869-3482
pISSN - 1869-3474
DOI - 10.1007/s13139-021-00703-9
Subject(s) - radionuclide therapy , medicine , peptide receptor , radioimmunotherapy , radionuclide imaging , thyroid , radioiodine therapy , nuclear medicine , radionuclide , radiation therapy , medical physics , thyroid cancer , receptor , physics , antibody , quantum mechanics , immunology , monoclonal antibody
This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very important role in the development of nuclear medicine. Since I-131 was used for thyroid therapy in 1959, other radionuclide therapy is still being used, and attempts to use new radionuclide are increasing. In this review, we briefly summarize and introduce the therapies such as radioimmunotherapy, transarterial radioembolization, radionuclide therapy for neuroendocrine tumors, peptide receptor radionuclide therapy, control of metastatic bone pain, radiation synovectomy, radionuclide brachytherapy, alpha particle therapy, and boron neutron capture therapy, which has been being attempted so far in the field of nuclear medicine.